earnings
confidence high
sentiment neutral
materiality 0.60
Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%
Zomedica Corp.
2024-Q3 EPS
reported -$0.04
vs consensus $0.00
▼ miss
(-4000000.0%)
- Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.
- Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).
- Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).
- Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.
- Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change.